ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care - OncoDaily ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care / ADCs, Antibody drug conjugates, Breast Cancer, cancer, Dana-Farber Cancer

ESMO Daily Reporter Interviewed Paolo Tarantino on ADCs in Breast Cancer Care
@myesmo.bsky.social @ptarantinomd.bsky.social

oncodaily.com/blog/paolo-t...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMODailyReporter #BreastCancer #ADCs

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More - OncoDaily Linda Evangelista reveals her breast cancer journey, emphasizing early detection, resilience, and hope after diagnosis and treatment.

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

oncodaily.com/stories/cele...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BreastCancer

Ashley Love Sumrall: Reflecting on Experiences After ASCO and AMA Meetings - OncoDaily Ashley Love Sumrall: Reflecting on Experiences After ASCO and AMA Meetings / AMA, ASCO, Ashley Love Sumrall, cancer, OncoDaily, Oncology

Reflecting on Experiences After ASCO and AMA Meetings - Ashley Love Sumrall
@ashleysumrallmd.bsky.social @ascocancer.bsky.social

oncodaily.com/blog/asco-an...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ASCO #AMA

Dana-Farber Oncologist Brings LGBTQ+-Centered Health Expertise Abroad Published: May 19, 2025Updated: June 2, 2025Written by: Lukas Harnisch-WeidauerJyoti Bajpai, MD, DM, an oncologist practicing in the Apollo Hospital network in India, is well versed in treating rare cancers, but when she encountered someone with prostate cancer who was undergoing gender-affirming hormone replacement therapy, she found surprisingly little data to inform her approach.  The ... Read more

Shail Maingi, MD, brought her experience in LGBTQ+ inclusive cancer care to India, supporting efforts to better serve LGBTQ+ patients.

Read how this global effort is supporting more inclusive care: bit.ly/4dBsI4M

Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer.

We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!

@oncbrothers.bsky.social
@oncoalert.bsky.social

www.astrazeneca.com/media-centre...

Dr. @hoperugo.bsky.social presents data from 5️⃣ 🇺🇸centers on re-challenge after G1 ILD with T-DXd (n=44), and a small # (n=19) G2 ILD rechallenged.

27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25

@oncoalert.bsky.social

ASCENT04 changes practice w/ improved mPFS 11.2 vs. 7.8 mos; 12 mon PFS 48 vs 33 mos w/ impressive tail suggesting potential for group with durable sustained response; adverse events were not additive. Bonus points for cr up oss over design. #ASCO25 @oncoalert.bsky.social

Check out the newest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (June 1st-6th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Dr. Sara Tolaney @stolaney1.bsky.social shares key take-aways from #ASCO25. #BreastCancer #SERENA6 #MBC #MetasticBreastCancer Watch the video here:
touchoncology.com?p=138380&pos...

@dfcibreastonc.bsky.social is leading the ADEPT study, examining the non-chemotherapy combination of HER2-directed therapy (trastuzumab and pertuzumab) + hormonal therapy as a treatment after surgery for early HR+/HER2+ #BreastCancer. Call 877-338-7425 or visit:
www.dana-farber.org/clinical-tri...

One of my most favorite slides form #ASCO25 from the CHALLENGE Trial showing exercise can match or beat drug effects. Powerful data

Abi Siva MD on X: "ER+/HER2-bca relapsing on adjuvant abemaciclib - @DFCI15/163 (9.2%) pts recurred after adjuvant abema, Median durations: 8.0 mo (abema), 18.5 mo (ET), 3.0 mo (1Lmtx). In 12 w/ paired bx, 50% lost ER; 90% of 10 had p53 alterations at recurrence. No RB1 loss https://t.co/j6t1cLpyJh" / X ER+/HER2-bca relapsing on adjuvant abemaciclib - @DFCI15/163 (9.2%) pts recurred after adjuvant abema, Median durations: 8.0 mo (abema), 18.5 mo (ET), 3.0 mo (1Lmtx). In 12 w/ paired bx, 50% lost ER; 90% of 10 had p53 alterations at recurrence. No RB1 loss https://t.co/j6t1cLpyJh

x.com/abisivamd/st...

Acknowledging Racism, Building Trust — Conversations That Matter in Maternal Medicine | NEJM Recognizing their increased risks during pregnancy and frustrated by the slow pace of change, an Ob/Gyn decides to discuss racism and risks with Black and Indigenous patients at their first visit.

Thoughtful, provocative (in the best way) and helpful essay on why and how to talk with patients about racial disparities and excess risk attributable to racism. www.nejm.org/doi/full/10....

AMA to Advocate for IMGs in Visa Limbo Due to Trump Policies Delayed appointments for J-1 visas is a 'healthcare delivery emergency,' one delegate said

New interns start in 20 days. At some hospitals 100% of residents are IMGs. These mostly serve the most needy areas, and these systems are going to collapse if the travel ban, with no exceptions for physicians, stays in place. www.medpagetoday.com/meetingcover...

Another highly anticipated readout: Trodelvy + Keytruda shows statistically significant & clinically meaningful PFS improvement in 1L PD-L1+ mTNBC! Big news for frontline treatment

www.gilead.com/news/news-de...

Happy to be part of the #ASCOAdvocacysummit Day2 - training session- powerful training from oncology leaders and legislators committed to advancing cancer policy. Grateful for the insights, momentum, and shared mission to improve care for all patients.

Great to be #ASCOAdvocacysummit reception today, surrounded by passionate advocates united in the mission to improve cancer care. Nearly 180 advocates from across the country have come together to drive change. Proud to represent SC @MUSC. @ishwaria.bsky.social @drsgraff.bsky.social

Only a few hours left to submit your abstract to #ESMOBreast! A lot is happening in the world, but let’s keep pushing forward with research and innovation. Just submitted mine—good luck to everyone submitting! 💪 #bcsm

Figure. TRAIN’s Relationship to Other Entities in the Evolving Health Artificial Intelligence (AI) Ecosystem

Viewpoint: The Trustworthy and Responsible AI Network (TRAIN), established by multiple health systems and
@microsoft.com, aims to advance the safe, effective, and equitable use of #AI in health care.

ja.ma/3WUsQ89

#MedSky

Congratulations all!! @stolaney1.bsky.social @lymphomadoc.bsky.social @ryannipp.bsky.social and more! #FASCO

Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social

#MedSky
You can contact your elected officials in Congress even if you don’t know who they are. Call the Congressional switchboard (📸 below), & they will connect to the right Rep/Senators based on your address. You can also find them online here: www.congress.gov/members/find...

Join us 2/1/25 at the Hilton Columbus at Easton @osucccjames.bsky.social Update from the #SABCS24 👋Experts from #TheJames @mskcancercenter.bsky.social #Emory will address the latest insights and practical guidance presented at #SABCS24. Register here 👉 ccme.osu.edu/continuing-m...

Genentech: Press Releases | Monday, Jan 27, 2025 Discover the latest news about our company, our products, our policies, and our people.

www.gene.com/media/press-... @oncoalert.bsky.social

Abema + ET

A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel - PubMed The use of cryotherapy decreased the occurrence of CTCAE grade ≥ 2 PN by 55%. Cold intolerance was the most frequently reported adverse effect associated with cryotherapy, but this adverse effect did ...

Sharing our recent meta-analysis on the utility of cryotherapy in preventing peripheral neuropathy among #breastcancer patients. #oncsky #bcsm
pubmed.ncbi.nlm.nih.gov/39827229/
Sensory PN: RR = 0.19 [0.05–0.66], p = 0.009
Motor PN: RR = 0.18 [0.03–0.99], p = 0.0491

A bar chart of the percentage of women who had a new morphometric vertebral fracture during 10 years of follow-up, stratified according to trial group.

Zoledronate administered every 12 to 18 months prevents fractures in older women. Ten years after initiation of this trial, zoledronate administered at baseline and 5 years prevented vertebral fracture. Full trial results: nej.md/4g6wlz3

#MedSky #OrthoSky

Join Dr. Sara Tolaney (@stolaney1.bsky.social) tomorrow at #SABCS24 for an insightful #CareerDevelopment session, focused on early funding for research. Dr. Tolaney will discuss the importance of having foundation and community program support.
🗓️ Dec 10th
⏰12:00–1:45 pm CST (1:00 pm EST)
📍Rm 221ABC

What You Should Know About Alcohol Consumption and Cancer Risk  Discover the connection between alcohol consumption and elevated cancer risk.

Raise your awareness before you raise your glass. Discover how alcohol consumption could impact your cancer risk and the steps you can take to prioritize your health.

What changed Monday morning? Summary slide #SABCS24